Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T13:36:36.074Z.
Calculation as of: 2026-10-06T13:36:36.074Z.
Quote observation: 2026-10-06T13:35:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6da64a8b1a2a274dcb8686c6d20e6c80d542b1d2a14b58c5ff35188fa74041c0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$5.97M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.98M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.52M
Price/FCF Ratio
N/A
TTM Avg
1251.36
3Y Avg
3596.79
5Y Avg
3596.79
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Femasys Inc. (FEMY) | $6.25M | N/A | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.23M | N/A | N/A | N/A | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.97M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | N/A | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.52M | N/A | 1251.36 | 3596.79 | 3596.79 |
| Biomerica, Inc. (BMRA)vs › | $6.40M | N/A | 129.84 | 129.84 | 129.84 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.67M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $6.65M | N/A | N/A | N/A | N/A |
| Aclarion, Inc. (ACON)vs › | $6.78M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.85M | N/A | 2104.37 | 2470.51 | 5857.68 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
